BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36074313)

  • 1. CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
    Xu B; Li S; Kang B; Fan S; He Z; Zhou J
    Invest New Drugs; 2022 Dec; 40(6):1333-1341. PubMed ID: 36074313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.
    Epperla N; Hamadani M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):19-24. PubMed ID: 33492560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
    Hamadani M; Collins GP; Caimi PF; Samaniego F; Spira A; Davies A; Radford J; Menne T; Karnad A; Zain JM; Fields P; Havenith K; Cruz HG; He S; Boni J; Feingold J; Wuerthner J; Horwitz S
    Lancet Haematol; 2021 Jun; 8(6):e433-e445. PubMed ID: 34048682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
    Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
    Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
    Xu B
    Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
    Toukam M; Boni JP; Hamadani M; Caimi PF; Cruz HG; Wuerthner J
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):1-12. PubMed ID: 36333463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
    Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
    Toukam M; Wuerthner J; Havenith K; Hamadani M; Caimi PF; Kopotsha T; Cruz HG; Boni JP
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):13-24. PubMed ID: 36333464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond.
    Desai S; Ansell SM
    Leuk Lymphoma; 2021 Aug; 62(8):1795-1804. PubMed ID: 33602008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
    Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
    Grover NS; Dittus C; Thakkar A; Beaven AW
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy.
    Maaroufi M
    Crit Rev Oncol Hematol; 2023 Feb; 182():103923. PubMed ID: 36702422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
    J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
    Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
    Goyal SD; Bartlett NL
    Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine.
    Himed S; Chung C; Dulmage B; Jaglowski S; Bond D; Maddocks K; Kaffenberger BH
    J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):e890-e893. PubMed ID: 36800311
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
    Mei M; Thomas S; Chen R
    BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.